Fiscal 2018 Second Quarter Highlights Net sales of $86.7 million , a decrease of 2.6% year over year U.S. GAAP EPS of $0.01 ; Adjusted EPS of $0.16 per share Operating cash flow of $10.2 million ; free cash flow of $9.4 million LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 19, 2017-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Jim Clemmer , President and Chief Executive Officer,

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 11, 2017-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report financial results for the second

Q1 net sales of $85.4 million , down 3% year-over-year              Q1 GAAP earnings per share of $0.00 ; adjusted EPS of $0.12 Q1 operating cash generation of $3.0 million ; free cash flow generation of $2.5 million Company reaffirms fiscal 2018 guidance ALBANY, N.Y. , Sept.

Low rates of major PICC-associated complications attributed in-part to the novel BioFlo catheter material Data to be presented at AngioDynamics -sponsored symposium at the annual scientific meeting of the Association for Vascular Access ALBANY, N.Y. , Sept.

ALBANY, N.Y. , Sept. 14, 2017 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2018 first

ALBANY, N.Y. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Michael C.

ALBANY, N.Y. , Aug. 29, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer and

ALBANY, N.Y. , Aug. 07, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Michael Greiner , Executive Vice President and Chief

Company posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance Q4 net sales of $86.9 million , down 7% year-over-year Q4 GAAP loss per share of $0.30 ; adjusted EPS of $0.19 Full Year net sales of $349.6 million , down 1% year-over-year Full Year GAAP earnings

ALBANY, N.Y. , July 07, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 fourth

ALBANY, N.Y. , June 07, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology/surgery, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k)

ALBANY, N.Y. , May 31, 2017 (GLOBE NEWSWIRE) -- C.R. Bard has illegally tied the sale of its tip location systems to its line of peripherally inserted central catheters ("PICCs"), violating federal antitrust laws, preventing competition in the marketplace and limiting patient access to superior

ALBANY, N.Y. , May 09, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Michael C. Greiner , Executive Vice President and Chief

ALBANY, N.Y. , April 20, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer, is

ALBANY, N.Y. , April 06, 2017 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the "Company"), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the pricing of the previously announced

ALBANY, N.Y. , April 06, 2017 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the "Company"), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that certain of its stockholders (the

Q3 net sales of $85.6 million , down 2% year-over-year Q3 GAAP earnings per share of $0.08 ; non-GAAP adjusted EPS up 27% from Q3 fiscal 2016 Q3 operating cash generation of $14.4 million ; free cash flow generation of $14.0 million Revised FY2017 revenue and adjusted EPS guidance; free cash flow

ALBANY, N.Y. , March 27, 2017 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, will host an Investor Day on April 6, 2017 in New York City , beginning at

ALBANY, N.Y. , March 20, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 third